Meetu Agrawal, Ravin J. Garg, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek and Alfonso Quintas-Cardama Experimental therapeutics for patients with myeloproliferative neoplasias Cancer 117
Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) such as essential thrombocythemia, polythemia vera, and primary myelofibrosis, have been historically managed with palliative intent. Recently, small molecule inhibitors of Janus kinase (JAK) 2, a kinase frequently mutated in MPNs, has spurred the development of novel therapeutics. Other novel non-tyrosine kinase inhibitor approaches such as immunomodulatory agents and pegylated interferon-α have also shown promising results in MPNs.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf